Osteoporosis
Conditions
Interventions
All participants will visit the AMC on three different occasions. On the first
two days subjects will receive either a single oral dose of clonidine 0.3mg or
no intervention. Participants will be ra
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age: 18-70 years
Exclusion criteria
Exclusion criteria: - Hypersensitivity to the active substrate or to any of the excipients - Severe bradycardia, like sick sinus syndrome and a second or third degree atrioventricular block - Use of antihypertensive drugs (including diuretics) - Use of drugs with negative effects on heart rhythm - Any medication or disease influencing bone turnover - Inability to give informed consent - RR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the change in serum concentrations of collagen type 1 cross-linked C-telopeptide (CTX) on the intervention and on the control day. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objective is the change in catecholamine levels and serum concentration of another bone turnover marker, procollagen type I N propeptide (P1NP) on the intervention day (clonidine 0.3mg) and on the control day (no intervention). We will also investigate whether osteoclasts are responsive to the alpha2-adrenoceptor agonist clonidine in vitro, by measuring osteoclast activity and formation. | — |
Countries
Netherlands
Outcome results
None listed